Go Pro
→ Earth's biggest energy source: near Grand Canyon (From Behind the Markets) (Ad)tc pixel Free AGY Stock Alerts

Allergy Therapeutics (AGY) Competitors

Allergy Therapeutics logo
GBX 5 +0.25 (+5.26%)
As of 09/11/2026 06:06 AM Eastern
Compare

AGY vs. VEC, ERGO, BMY, AMYT, and APH

Should you buy Allergy Therapeutics stock or one of its competitors? Allergy Therapeutics's main competitors and comparable companies include Vectura Group (VEC), Ergomed (ERGO), Bloomsbury Publishing (BMY), Amryt Pharma (AMYT), and Alliance Pharma (APH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Allergy Therapeutics compare to Vectura Group?

Vectura Group (LON:VEC) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Vectura Group has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vectura Group£190.60M0.00N/A£20.10N/A
Allergy Therapeutics£57.29M5.53-£52.59M-£0.97N/A

In the previous week, Vectura Group's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Vectura Group Neutral
Allergy Therapeutics Neutral

Vectura Group has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Vectura Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Vectura GroupN/A N/A N/A
Allergy Therapeutics -85.46%409.00%-34.76%

0.0% of Allergy Therapeutics shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vectura Group beats Allergy Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Allergy Therapeutics compare to Ergomed?

Allergy Therapeutics (LON:AGY) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Ergomed has a net margin of 9.87% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Ergomed's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Ergomed 9.87%18.08%10.16%

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Ergomed Neutral

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by company insiders. Comparatively, 18.2% of Ergomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Allergy Therapeutics has a beta of 0.835, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Ergomed has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M5.53-£52.59M-£0.97N/A
Ergomed£152.09M0.00£15M£0.29N/A

Summary

Ergomed beats Allergy Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Allergy Therapeutics compare to Bloomsbury Publishing?

Allergy Therapeutics (LON:AGY) and Bloomsbury Publishing (LON:BMY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Bloomsbury Publishing has a net margin of 8.28% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Bloomsbury Publishing's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Bloomsbury Publishing 8.28%12.74%7.82%

Allergy Therapeutics has a beta of 0.835, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Bloomsbury Publishing has a beta of 0.418, suggesting that its stock price is 58% less volatile than the broader market.

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 42.2% of Bloomsbury Publishing shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Bloomsbury Publishing shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Bloomsbury Publishing had 4 more articles in the media than Allergy Therapeutics. MarketBeat recorded 4 mentions for Bloomsbury Publishing and 0 mentions for Allergy Therapeutics. Allergy Therapeutics' average media sentiment score of 0.00 beat Bloomsbury Publishing's score of -0.13 indicating that Allergy Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Allergy Therapeutics Neutral
Bloomsbury Publishing Neutral

Bloomsbury Publishing has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M5.53-£52.59M-£0.97N/A
Bloomsbury Publishing£325.90M1.54£37.37M£32.8018.98

Bloomsbury Publishing has a consensus price target of GBX 800, indicating a potential upside of 28.52%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, analysts plainly believe Bloomsbury Publishing is more favorable than Allergy Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allergy Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Bloomsbury Publishing
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Bloomsbury Publishing beats Allergy Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Allergy Therapeutics compare to Amryt Pharma?

Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Amryt PharmaN/A N/A N/A
Allergy Therapeutics -85.46%409.00%-34.76%

In the previous week, Amryt Pharma's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Amryt Pharma Neutral
Allergy Therapeutics Neutral

0.0% of Allergy Therapeutics shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amryt Pharma£210.24M0.00N/A-£33.00N/A
Allergy Therapeutics£57.29M5.53-£52.59M-£0.97N/A

Summary

Amryt Pharma and Allergy Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Allergy Therapeutics compare to Alliance Pharma?

Alliance Pharma (LON:APH) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Alliance Pharma has a net margin of -6.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Alliance Pharma-6.00% -5.04% 5.98%
Allergy Therapeutics -85.46%409.00%-34.76%

In the previous week, Alliance Pharma's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Alliance Pharma Neutral
Allergy Therapeutics Neutral

66.3% of Alliance Pharma shares are held by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are held by institutional investors. 12.0% of Alliance Pharma shares are held by company insiders. Comparatively, 3.6% of Allergy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alliance Pharma has higher revenue and earnings than Allergy Therapeutics. Alliance Pharma is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A
Allergy Therapeutics£57.29M5.53-£52.59M-£0.97N/A

Alliance Pharma has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.835, indicating that its share price is 17% less volatile than the broader market.

Summary

Alliance Pharma beats Allergy Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Allergy Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGY vs. The Competition

Export
MetricAllergy TherapeuticsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£316.63M£12.46B£7.16B£2.87B
Dividend Yield8.33%2.62%2.56%6.23%
P/E Ratio-5.15799.74274.10366.83
Price / Sales5.53763.35656.0083,599.70
Price / Cash3.6689.2577.0427.89
Price / Book50.6710.3910.336.33
Net Income-£52.59M£2.85B£3.50B£5.89B
7 Day Performance-7.37%-3.70%-3.35%-0.69%
1 Month Performance-4.58%0.78%-0.43%0.18%
1 Year Performance-39.76%3.48%19.21%20.03%

Allergy Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
N/AGBX 5
+5.3%		N/A-39.8%£316.63M£57.29MN/A612
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
BMY
Bloomsbury Publishing
2.8073 of 5 stars		GBX 626.19
-2.6%		GBX 800
+27.8%		+23.3%£506.23M£325.90M19.0934,300
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24MN/A290

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AGY) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Shocking AI prediction from the “Billionaire Whisperer"
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The retirement income that answers “yes” when everything else says no
Todd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...
Eagle Publishing | Sponsoredtc pixel
My ‘one day’ retirement secret
TradeSmith's AI research team, backed by a $17 million investment and led by a former NSA codebreaker, built a...
TradeSmith | Sponsoredtc pixel